Session » Infection-related Rheumatic Disease Poster

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0255

“Rheum” to Improve: Have Patients Attending the Young Adult Systemic Erythematosus (YASLE) Clinic Received All Appropriate Vaccinations? A Quality Improvement Initiative

10:30AM-12:30PM: Abstract Number: 0244

Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series

10:30AM-12:30PM: Abstract Number: 0241

Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients

10:30AM-12:30PM: Abstract Number: 0256

Anti-TNF Therapy as a Potential Risk of Leishmania Infections

10:30AM-12:30PM: Abstract Number: 0262

Bartonella Endocarditis as an Important Mimic of ANCA Associated Vasculitis: Results of a Large Single Center Descriptive Analysis

10:30AM-12:30PM: Abstract Number: 0240

Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0263

Characteristics and Coinfections of Diffuse Alveolar Hemorrhage in Rheumatic Patients

10:30AM-12:30PM: Abstract Number: 0261

Clinical Implications, Bacterial Profiles, and Patient Outcomes in Hospitalized Patients with Autoimmune Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 0264

Clinical Value of Metagenomic Next-generation Sequencing in Patients with Connective Tissue Disease Co-infections: A Single-center Study from Southern Hospital in China

10:30AM-12:30PM: Abstract Number: 0250

Effectiveness of Tuberculosis Preventive Treatment in Patients with Rheumatic Diseases: A Global Meta-analysis of Cohort Studies

10:30AM-12:30PM: Abstract Number: 0247

Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study

10:30AM-12:30PM: Abstract Number: 0257

High Prevalence of Strongyloides Antibodies in Patients at Risk for Dissemination. A Call for Action

10:30AM-12:30PM: Abstract Number: 0243

Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment

10:30AM-12:30PM: Abstract Number: 0236

Impact of Socioeconomic Status on Infection-Related Hospitalization Risk in Patients with Systemic Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 0238

Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals

10:30AM-12:30PM: Abstract Number: 0260

National Survey on Patient’s Knowledge and Drivers of Human Papillomavirus (HPV) Vaccination in Immune-mediated Inflammatory Diseases (IMIDs)

10:30AM-12:30PM: Abstract Number: 0258

Nationwide Analysis of Adult Non-Gonococcal Bacterial Septic Arthritis Hospitalizations from the National Inpatient Sample 2016 to 2020

10:30AM-12:30PM: Abstract Number: 0239

Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0253

Outcomes of Respiratory Syncytial Virus Infection in Patients with Systemic Autoimmune Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 0252

Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 0249

Real World Evidence on the Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients with Rheumatic Diseases – Preliminary Results from a Prospective Multicenter Observational Greek Study

10:30AM-12:30PM: Abstract Number: 0248

Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study

10:30AM-12:30PM: Abstract Number: 0254

Rheumatic Manifestations in Patients with Hansen’s Disease Treated with Multidrug Antibiotic Therapy

10:30AM-12:30PM: Abstract Number: 0246

Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies

10:30AM-12:30PM: Abstract Number: 0251

T-SPOT.TB and TST in Diagnosing Active Tuberculosis in Patients with Rheumatic Immune Diseases: A Fully Paired Comparative Diagnostic Test Accuracy Study

10:30AM-12:30PM: Abstract Number: 0245

The Impact of COVID-19 and ‘Long COVID’ on Self-Reported Disease Activity, Disability, and Quality of Life in Patients with Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0237

Tofacitinib: A Retrospective Study on Safety and Adverse Effects

10:30AM-12:30PM: Abstract Number: 0242

Use of Outpatient Antiviral Therapy and Severe Outcomes from SARS-CoV-2 Omicron Infection in Patients with Immune Mediated Diseases on B Cell Depleting Agents

10:30AM-12:30PM: Abstract Number: 0259

Whipple’s Disease in Patients Initially Diagnosed with Rheumatic Diseases: A Case Series

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].